NCT02042443: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02042443 |
|---|---|
| Title | Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 28, 2014 |
| Completion date | Jan. 31, 2017 |
| Required reporting date | Jan. 31, 2018, midnight |
| Actual reporting date | July 12, 2017 |
| Date last checked at ClinicalTrials.gov | Aug. 28, 2025 |
| Days late | None |